PT  - JOURNAL ARTICLE
AU  - Rizzo, Toni
ED  - Havrdova, Eva
TI  - Risk Management of New DMTs
DP  - 2012 May 01
TA  - MD Conference Express
PG  - 18--19
VI  - 12
IP  - 2
4099  - http://mdc.sagepub.com/content/12/2/18.short
4100  - http://mdc.sagepub.com/content/12/2/18.full
AB  - DMTs for multiple sclerosis (MS) carry potentially serious risks, including opportunistic infections, altered response to vaccinations, development of cancer, and the appearance of autoimmune disorders. This article reviews safety data from clinical studies and post-marketing surveillance of DMTs for MS, as well as discusses the risks associated with such new therapies.